Rocket Pharmaceuticals, Inc. (RCKT) Stock

Rocket Pharmaceuticals, Inc. (RCKT) is a Healthcare stock trading at $3.50 (as of 2026-08-21), with a market capitalization of $384.21M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Rocket Pharmaceuticals, Inc. develops gene therapies for rare diseases, including clinical programs using ex vivo lentiviral vectors for Fanconi anemia, leukocyte adhesion deficiency type I, and pyruvate kinase deficiency, as well as an in vivo AAV program for Danon disease. It conducts research and development across these programs and operates through its subsidiaries.

Valuation — source: SEC EDGAR (first-party)
Price$3.50
Market Cap$384.21M
Price / Book1.04
FCF Yield-86.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Financial Health — source: SEC EDGAR
Altman Z-Score-3.55 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderRTW INVESTMENTS, LP ($63.32M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOGaurav D. Shah
Employees299
CountryUS
IPO Date2015-02-18

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Enanta Pharmaceuticals, Inc. (ENTA)
  • Arcturus Therapeutics Holdings Inc. (ARCT)
  • Lyell Immunopharma, Inc. (LYEL)
  • Upstream Bio, Inc. (UPB)
  • Perspective Therapeutics, Inc. (CATX)
  • Galectin Therapeutics Inc. (GALT)
  • Capricor Therapeutics, Inc. (CAPR)
  • DiaMedica Therapeutics Inc. (DMAC)
RCKT earnings history · RCKT institutional & insider holders · RCKT KPIs & operating metrics · RCKT financials · RCKT investor presentations & press releases · RCKT SEC filings · RCKT peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.